Streetbeat News

Products Services

ZIVO

Zivo Bioscience has announced the results of a month-long coccidiosis trial in broiler chickens. The company stated that all test groups demonstrated a statistically significant benefit in broiler health under simulated commercial conditions.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 8:17 pm

BXP

Enel North America has signed a power purchase agreement with BXP, the largest publicly traded developer, owner, and manager of premier workplaces in the United States, for a 21-megawatt portion of the Estonian solar project under construction in Texas. The 202 MW solar project, paired with a 104 MW battery system, is expected to come online in late 2024. The agreement builds on a longstanding relationship between Enel and BXP for advanced energy solutions.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 8:17 pm

INTC

Intel Corporation's shares are trading lower due to a downward trend in semiconductor and chip stocks and news that Taiwan Semiconductor Mfg. Co. Ltd. has asked its suppliers to postpone high-end chipmaking equipment delivery. This could impact Intel's supply chain and production capabilities. Despite this, Intel introduced a range of technologies at its Intel Innovation 2023 event and its stock is up 41.87% year-to-date.

Portfolio Pulse from Ryan Gustafson

September 19, 2023 | 8:14 pm

ASMB

Assembly Biosciences, Inc. (NASDAQ:ASMB) will present new preclinical data from its hepatitis B and D virus (HBV/HDV) pipeline programs at the 2023 International HBV Meeting. The company will highlight progress in its HBV/HDV oral entry inhibitor program and its interferon-alpha receptor agonist program. The data for ABI-4334, Assembly Bio's capsid assembly modulator, supports its potential to prevent HBV DNA integration, a process linked to liver cancer in HBV patients. Assembly Bio anticipates nominating a development candidate from the HBV/HDV entry inhibitor program in 2023.

Portfolio Pulse from Happy Mohamed

September 19, 2023 | 8:10 pm

TSHA

Taysha Gene Therapies has decided to discontinue the development of its TSHA-120 program for the treatment of Giant Axonal Neuropathy (GAN) following feedback from the U.S. FDA. The decision was made due to challenges with study design feasibility for potential Biologics License Application (BLA) submission. Additionally, Astellas Gene Therapies has chosen not to exercise its option to obtain an exclusive license to TSHA-120 under the Option Agreement.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 8:03 pm

ATRA

Atara Biotherapeutics has announced its plans to submit a Biologics License Application (BLA) for Tab-cel in Q2 2024. This decision follows an agreement with the FDA on comparability.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 8:02 pm

SPY

TTWO

The article discusses the performance of Take-Two Interactive Software's (NASDAQ:TTWO) stock since the release of 'Grand Theft Auto V' 10 years ago. If an investor had put $1,000 into Take-Two stock at the time of the game's release, their investment would be worth $8,186.85 today, a return of 718.7%. This significantly outperforms the SPDR S&P 500 Global ETF, which would have turned $1,000 into $2,595.71, a return of 159.6%. The company is currently working on the next installment in the franchise, 'Grand Theft Auto 6/GTA VI', which could potentially boost Take-Two's shares further.

Portfolio Pulse from Chris Katje

September 19, 2023 | 7:52 pm

SHOT

Safety Shot Inc (NASDAQ:SHOT) plans to develop its functional beverage platform to treat alcohol poisoning in hospital and emergency settings. The beverage, set to launch in Q4 2023, reduces blood alcohol content and boosts clarity. It can lower blood alcohol content by up to 50% in 30 minutes. The company was formerly known as Jupiter Wellness Inc. and changed its name after acquiring Safety Shot. The shares of SHOT are currently down 2.11% at $1.39.

Portfolio Pulse from Vandana Singh

September 19, 2023 | 7:40 pm

GS

JPM

MS

Morgan Stanley has introduced a financial assistant powered by OpenAI’s generative AI software, marking Wall Street's entry into the generative AI domain. The AI-driven assistant is now operational for all the bank's financial advisors and their auxiliary staff. The tool offers advisors access to the institution’s expansive 'intellectual capital,' comprising roughly 100,000 research reports and documents. Morgan Stanley sees the tool as being the first in a lineage of generative AI-based solutions.

Portfolio Pulse from AJ Fabino

September 19, 2023 | 7:25 pm

BTCUSD

NMR

Nomura's digital asset subsidiary, Laser Digital Asset Management, has introduced a Bitcoin Adoption Fund for institutional investors. The fund is part of a Laser Digital Funds Segregated Portfolio Company registered under the Cayman Islands Regulatory Authority. Komainu, a collaboration between Nomura, Ledger, and Coinshares, will serve as the regulated custody partner. This move is part of Nomura's broader strategy to provide digital adoption investment solutions.

Portfolio Pulse from Khyathi Dalal

September 19, 2023 | 6:44 pm